Hospital Endoscopy Equipment Market

Every cross-contamination scare pushes hospitals further toward scopes they can throw away, and a disposable scope turns a capital purchase into a per-procedure cost. Douglas Insights values the hospital endoscopy equipment market at USD 13.6 billion in 2025 and expects USD 27.1 billion by 2035, compounding at 7.11%. The estimate is built from the bottom up: roughly 235 million endoscopic procedures performed in 2025 across gastrointestinal, pulmonary, urological, gynaecological and surgical specialties, at an average equipment spend of USD 58 per procedure covering flexible video endoscopes, visualization systems, processors and light sources, rigid endoscopes and surgical visualization, and single use endoscopes and artificial intelligence detection software (clinical AI in other specialties is sized in our AI in Mental Health Market report), triangulated against procedure volumes, installed bases and manufacturer disclosures. Procedures grow 4.8% a year as screening expands and ageing populations need more diagnosis, while equipment spend per procedure rises 2.2% a year as single use scopes, higher definition imaging and artificial intelligence raise content. This study sits within our diagnostic devices coverage and follows the published Douglas Insights methodology.

Why did infections push the market toward single use scopes?

Infections pushed hospital endoscopy equipment toward single use scopes because outbreaks of drug resistant bacteria in the 2010s were traced to duodenoscopes that had been reprocessed to manufacturer instructions. Regulators then required design changes, and single use endoscopes and AI software reached 16% of 2025 equipment value, USD 2.18 billion, the fastest growing category.

Some reusable endoscopes proved almost impossible to clean reliably, and outbreaks of drug resistant infections traced to them forced regulators and hospitals to rethink the model. Flexible endoscopes are long, narrow, complex instruments with internal channels and moving parts, and they are reprocessed between patients through cleaning and high level disinfection rather than full sterilisation. Duodenoscopes, used to access the bile and pancreatic ducts with devices such as those in our Biliary Balloon Dilatation Catheter Market report, have a particularly intricate tip mechanism, and in the 2010s several hospitals experienced outbreaks of antibiotic resistant bacteria transmitted between patients through contaminated duodenoscopes despite reprocessing that followed manufacturer instructions. Regulators responded by requiring design changes and recommending that hospitals transition to duodenoscopes with disposable components or fully single use designs. That opened a market for single use endoscopes, which eliminate reprocessing and cross contamination risk and have since spread to bronchoscopes, urological scopes and other types, particularly where reprocessing is costly or infection risk high. Single use scopes carry per procedure costs that shift spending from capital to consumables. The exclusive chapter of this report compares the cost per procedure of reusable and single use scopes by type, since that comparison drives adoption.

What is hospital endoscopy equipment, and which scopes, systems and specialties does it cover?

Hospital endoscopy equipment is the flexible scopes, video processors, light sources, rigid surgical scopes, single use scopes and AI detection software used for endoscopic procedures in hospitals and ambulatory surgery and endoscopy centres. Facilities spent USD 13.6 billion on it in 2025, about USD 58 for each of roughly 235 million procedures.

The study covers equipment used to perform endoscopic procedures in hospitals and ambulatory centres. Flexible video endoscopes cover reusable gastroscopes, colonoscopes, duodenoscopes, bronchoscopes, ureteroscopes and other flexible scopes. Visualization systems, processors and light sources cover the video processors, monitors, light sources and image management systems that endoscopes connect to. Rigid endoscopes and surgical visualization cover rigid scopes and camera systems used in laparoscopic, arthroscopic and other minimally invasive surgery. Single use endoscopes and artificial intelligence detection software cover disposable endoscopes and software that assists detection of lesions such as colorectal polyps. Endoscopic accessories and consumables such as biopsy forceps, snares and balloons covered in our separate biopsy and catheter coverage, endoscope reprocessing equipment covered in our sterile processing coverage, and surgical robots sit outside the boundary. Value is measured at the price facilities pay. By specialty, the study counts gastrointestinal, pulmonary, urology and gynaecology procedures as well as laparoscopic and orthopaedic surgery, where rigid scopes and camera systems are used; by setting, it counts hospitals and ambulatory surgery and endoscopy centres.

What is artificial intelligence changing in hospital endoscopy equipment?

Artificial intelligence is adding computer aided detection software to hospital endoscopy equipment, highlighting suspected colorectal polyps on the video feed in real time so fewer are missed. AI software is counted with single use scopes in a category worth USD 2.18 billion in 2025, 16% of the market and its fastest growing part.

Artificial intelligence is helping endoscopists see what they would otherwise miss, which in colorectal screening has direct consequences for cancer prevention. During colonoscopy, the endoscopist looks for polyps, some of which can develop into cancer, and removes them, but studies show that a meaningful share of polyps are missed, particularly small or flat ones, and miss rates vary widely between endoscopists. Computer aided detection systems analyse the video feed in real time and highlight suspected polyps on the screen, and clinical studies have shown they increase the rate at which polyps and adenomas are detected. Regulators have cleared such systems, and they are being adopted in screening programmes. Artificial intelligence is also being applied to characterise lesions, assess the quality of examinations, and support other endoscopic procedures. For this market, artificial intelligence adds software value to endoscopy systems and encourages upgrades to compatible platforms, and it supports the case for high quality screening. Its effect on procedure volume may be modest, but its effect on outcomes and on the value of equipment is growing.

What drives demand for hospital endoscopy equipment as screening widens and populations age?

Demand for hospital endoscopy equipment is driven by cancer screening, ageing populations, minimally invasive surgery and infection prevention. Screening and ageing lift procedures 4.8% a year, from about 235 million in 2025 to roughly 376 million in 2035, while single use scopes, higher definition imaging and AI lift equipment spend per procedure 2.2% a year.

Cancer screening is the first driver. Colorectal cancer screening programmes, including lower starting ages in some countries, and growing screening for gastric and lung cancers increase endoscopic procedure volumes. Screening is why procedures are the larger growth leg, 4.8 points of the 7.11% annual growth rate, and why North America, which screens for colorectal cancer from a younger age, holds 38% of 2025 value, USD 5.18 billion, while gastric screening in Japan and South Korea helps make Asia Pacific the fastest growing region at 8.5% a year.

Ageing populations are the second driver. Older people require more diagnostic and therapeutic endoscopy for gastrointestinal, pulmonary and urological conditions, adding procedures whatever happens to screening policy. Flexible video endoscopes, the scopes used for those gastrointestinal and pulmonary examinations, carry 38% of 2025 value, USD 5.18 billion, and their large replacement demand grows with the older patient base.

Minimally invasive surgery is the third driver. The continued shift from open to minimally invasive laparoscopic and orthopaedic surgery drives demand for rigid endoscopes and surgical visualization, a category worth 22% of 2025 value, USD 3.00 billion.

Infection prevention is the fourth driver. Concern about cross contamination, sharpened by the duodenoscope outbreaks of the 2010s, drives adoption of single use scopes and better reprocessing. Single use endoscopes and AI software hold 16% of 2025 value, USD 2.18 billion, and grow fastest, which is a large part of why equipment spend per procedure rises 2.2% a year from USD 58.

What holds back hospital endoscopy equipment spending when capital budgets tighten?

Hospital endoscopy equipment spending is held back by tight capital budgets, the cost and waste of single use scopes, and supplier concentration with quality problems. In the constrained-budget scenario, where capital is tight and single use adoption stalls, procedures grow 3.2% and spend per procedure 1.0% a year, leaving the market near USD 20.2 billion in 2035 instead of USD 27.1 billion.

Capital budgets are the first restraint. Endoscopy systems and scope fleets are significant capital purchases that compete with other hospital priorities, and replacement can be deferred. A reusable flexible endoscope costs tens of thousands of dollars and a video processor and tower cost more, and visualization systems, processors and light sources alone carry 24% of 2025 value, USD 3.27 billion, in upgrades that a stretched budget can postpone.

Single use cost and sustainability are the second restraint. Single use scopes cost from several hundred to over a thousand dollars each, against an average equipment spend of USD 58 per procedure, and they create medical waste. Debate about their environmental impact and cost effectiveness limits adoption in high volume colonoscopy, where reusable scopes remain more economical.

Market concentration and quality issues are the third restraint. A small number of manufacturers dominate flexible endoscopy, the category worth 38% of 2025 value, and regulatory actions over quality at a leading manufacturer have caused supply and compliance concerns that affect hospitals’ procurement. Each 1-point change in procedure growth moves the 2035 figure by roughly USD 2.48 billion.

Which hospital endoscopy equipment categories carry the value, and which grows fastest?

Flexible video endoscopes carry the most value in hospital endoscopy equipment, 38% of 2025 spend, USD 5.18 billion, because they are the core of gastrointestinal and pulmonary endoscopy and are replaced in large numbers. Single use endoscopes and AI detection software are the smallest category, at 16%, but grow fastest as single use scopes spread.

Visualization systems, processors and light sources hold 24%, USD 3.27 billion, upgraded periodically to higher definition and enhanced imaging. Rigid endoscopes and surgical visualization account for 22%, USD 3.00 billion, on laparoscopic and orthopaedic surgery. Single use endoscopes and artificial intelligence detection software contribute 16%, USD 2.18 billion. The four category models run to 2035 by specialty and region.

Category value follows the shift from capital to consumables. Reusable flexible scopes and the towers they plug into together hold 62% of 2025 value, but every single use scope bought replaces part of a reusable scope’s amortised cost with a per procedure purchase. That is why the 16% single use and AI category grows fastest and pushes average spend from USD 58 per procedure in 2025 to about USD 59.3 in 2026. Single use ureteroscopes in urology and bronchoscopes in intensive care units are where the shift is furthest along.

Where is hospital endoscopy equipment bought, and why does Asia Pacific grow fastest?

Hospital endoscopy equipment is bought mostly in North America, which holds 38% of 2025 value, USD 5.18 billion, on high procedure volumes and early single use and AI adoption. Asia Pacific grows fastest, at 8.5% a year, on gastric cancer screening in Japan and South Korea, rapid growth of endoscopy in China and expanding access in India.

North America grows 6.4% a year, reflecting high procedure volumes, colorectal screening from a younger age, and early adoption of single use scopes and artificial intelligence. Asia Pacific holds 28%, USD 3.82 billion, and Europe 26%, USD 3.54 billion, growing at 6.2% with established screening programmes. Latin America contributes USD 545.2 million at 7.8%, the Middle East USD 408.9 million at 8.4% and Africa USD 136.3 million at 7.6%. Six regional models sum to the global figure, with country tables in the Excel model.

North America’s endoscopy story is early adoption. The region reaches USD 9.63 billion in 2035, but at 6.4% a year its share slips from 38% to about 36% as faster growing Asia Pacific gains ground, even though the region adopted single use scopes and AI detection earliest.

Asia Pacific’s story is procedure volume. Gastric screening in Japan and South Korea, rapid growth of endoscopy in China and expanding access in India and Southeast Asia take the region from USD 3.82 billion in 2025 to USD 8.62 billion in 2035, lifting its share from 28% to about 32% and narrowing the gap with North America to about USD 1.01 billion.

Europe’s story is established screening. Organised screening programmes keep procedure volumes steady, and the region grows from USD 3.54 billion in 2025 to USD 6.47 billion in 2035 at 6.2% a year, the slowest of the three large regions. Latin America passes USD 1 billion, reaching USD 1.16 billion in 2035, while the Middle East reaches USD 916.1 million and Africa USD 283.5 million.

Who supplies hospital endoscopy equipment, and what is each supplier’s position built on?

Hospital endoscopy equipment is led by Olympus in flexible endoscopes, the category worth 38% of 2025 value, USD 5.18 billion, with Fujifilm and Pentax Medical as the other major flexible scope makers. Karl Storz, Stryker and Richard Wolf compete in rigid surgical visualization, worth USD 3.00 billion, and Ambu and Boston Scientific in single use scopes.

Olympus is the dominant supplier of flexible endoscopes worldwide, particularly in gastrointestinal endoscopy, though regulatory actions concerning quality at some of its facilities have created compliance challenges. Fujifilm and Pentax Medical, part of Hoya, are the other major flexible endoscope manufacturers. Karl Storz, Stryker, Richard Wolf and Olympus supply rigid endoscopes and surgical visualization. Ambu is a leading supplier of single use endoscopes, and Boston Scientific supplies single use duodenoscopes and ureteroscopes. Medtronic and others supply artificial intelligence detection systems. Chinese manufacturers including Sonoscape and Aohua have grown in their domestic market and are expanding abroad. The competitive chapter profiles each supplier’s product range, installed base, single use and artificial intelligence position and regional presence.

Supplier shares are not published in this edition. Concentration is clearest in flexible endoscopy, where three manufacturers, Olympus, Fujifilm and Pentax Medical, supply the category that carries 38% of value, which is also why quality actions at a leading manufacturer reach hospitals’ procurement so directly.

How much does hospital endoscopy equipment cost per procedure?

Hospital endoscopy equipment costs an average of USD 58 per procedure in 2025, the amortised cost of reusable scopes and systems across many procedures plus single use scope purchases where used. The figure rises 2.2% a year, to about USD 59.3 in 2026, as single use scopes, higher definition imaging and AI software add content.

A reusable flexible endoscope costs tens of thousands of dollars and is used for many procedures, with repair costs significant over its life, while a video processor and tower cost more. Single use endoscopes cost from several hundred to over a thousand dollars each depending on type, a large per procedure cost compared with reusable scopes but avoiding reprocessing and repair. Artificial intelligence software is sold as licences or subscriptions. Manufacturers frequently offer fleet agreements covering scopes, systems, repair and service over several years. The pricing chapter publishes price bands by equipment type and the per procedure cost of reusable and single use scopes.

How far apart do the constrained-budget and screening-expansion scenarios put hospital endoscopy equipment by 2035?

Hospital endoscopy equipment lands between about USD 20.2 billion and more than USD 33.8 billion in 2035 across the scenarios, with the base case at USD 27.1 billion. The spread depends on whether screening widens and single use scopes and AI spread, or capital stays tight and single use adoption stalls on cost and sustainability.

The base case carries 4.8% growth in procedures and 2.2% growth in equipment spend per procedure for a 7.11% revenue CAGR and USD 27.1 billion in 2035. The constrained-budget scenario, in which hospital capital is tight and single use adoption stalls on cost and sustainability, sets the legs at 3.2% and 1.0%, landing near USD 20.2 billion. The screening-expansion scenario, in which screening widens, single use scopes spread and artificial intelligence is standard, sets them at 6.0% and 3.4%, carrying the market past USD 33.8 billion. Each 1-point change in procedure growth moves the 2035 figure by roughly USD 2.48 billion.

The scenarios pull on different categories. In the constrained-budget case, single use scopes stall on cost and sustainability, slowing the 16% category that drives spend per procedure; in the screening-expansion case, wider screening lifts procedures 6.0% a year, which benefits flexible video endoscopes and visualization systems, together 62% of 2025 value.

Which device regulations and reprocessing standards shape hospital endoscopy equipment purchases?

Hospital endoscopy equipment is shaped by three layers of rules: medical device regulation of scopes, systems and AI software; reprocessing standards for reusable scopes; and national cancer screening guidelines. Reprocessing rules matter most for the equipment mix, because they raise the cost of reusable scopes and support the single use category, 16% of 2025 value.

Three layers matter. Medical device regulation comes first: endoscopes, visualization systems and artificial intelligence software are regulated medical devices requiring clearance, and regulators have required design changes and additional testing for endoscopes linked to infection risk. Reprocessing standards and guidance are second: standards and regulatory guidance for cleaning and disinfecting reusable endoscopes, and requirements for validated reprocessing instructions, affect the cost and risk of reusable scopes and support the case for single use designs. Cancer screening guidelines are third: national screening guidelines, including recommended starting ages and intervals for colorectal screening, drive procedure volumes. The regulatory chapter maps these requirements by jurisdiction.

Is single use the future of hospital endoscopy equipment?

Single use is the future for certain hospital endoscopy equipment, mainly intensive care bronchoscopes, duodenoscopes and urology ureteroscopes, but reusable scopes stay dominant overall through 2035. Single use scopes and AI software hold 16% of 2025 value, USD 2.18 billion, against 38% for reusable flexible video endoscopes, and high volume colonoscopy remains reusable.

The balance depends on cost, infection risk and sustainability. Single use scopes make the strongest case where infection risk is high, reprocessing is difficult or expensive, and procedure volumes are low or unpredictable: bronchoscopes in intensive care units, where urgent procedures happen around the clock and reprocessing capacity is limited; duodenoscopes, where contamination has been a documented problem; and ureteroscopes, which suffer frequent costly damage. In high volume gastrointestinal endoscopy such as colonoscopy, where reusable scopes are used many times a day and reprocessing is well established, reusable scopes generally remain more economical, and the waste generated by single use scopes raises environmental concerns that hospitals increasingly weigh. The likely outcome is a mixed model, with single use scopes gaining a substantial share in specific applications and reusable scopes remaining the norm for high volume procedures. The model reflects single use growth concentrated in these applications.

Douglas Exclusive: the reusable versus single use cost model

The reusable versus single use cost model is a Douglas Insights model, an estimate rather than published hospital data. It models, by scope type and facility, the total cost per procedure of reusable scopes including purchase, reprocessing, repair and infection risk, against single use scopes including purchase and waste disposal, identifying where each is more economical and converting procedure forecasts into equipment demand by category and region. Licence holders receive it as a maintained tab in the Excel model.

Methodology and receipts

The model is built bottom-up from procedures: endoscopic procedure volumes by specialty and region, installed scope and system bases, replacement cycles, single use and artificial intelligence adoption, and realised prices from manufacturer disclosures, with endoscopic accessories, reprocessing equipment and surgical robots excluded. Every figure carries a numbered source and a confidence grade in the fact sheet above, and the working model ships with every licence. In numbers, the headline is about 235 million procedures multiplied by USD 58 of equipment spend, giving USD 13.6 billion in 2025; the 7.11% growth rate compounds 4.8% procedure growth with 2.2% growth in spend per procedure; four category models and six regional models sum to the global figure; and three scenarios bracket 2035 between about USD 20.2 billion and more than USD 33.8 billion. Douglas Insights uses AI drafting tools and automated consistency checks to assemble and test this page; the research desk chooses the sources, builds the model and approves every figure before publication, as set out in our editorial standards. The next scheduled review of this study is April 2027.